AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06008093
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV Tremelimumab q3w for four 21-days cycles as induction treatment. Tremelimumab will also be given during the maintenance therapy phase at week 16 and week 104 (at the investigators discretion).
Trial: NCT06008093
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants in Arm A and Arm B will receive IV pemetrexed q3w for four 21-day cycles as induction treatment. In the maintenance therapy phase, Treatment Arm A will receive Pemetrexed q4w, Treatment Arm B will receive Pemetrexed q3w.
Trial: NCT06008093
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive IV pembrolizumab q3w for four 21-days cycles as induction treatment. Pembrolizumab will also be given in the maintenance treatment phase q3w until disease progression or unacceptable toxicity or up to 24 months.
Trial: NCT06008093
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive IV Carboplatin or IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles as induction treatment.
Trial: NCT06008093
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive IV Carboplatin or IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles as induction treatment.
Trial: NCT06585488
Drug: BGB-53038
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06585488
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered by intravenous infusion
Trial: NCT06585488
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered by intravenous infusion
Trial: NCT05879926
Drug: Adjuvant Chemotherapy + Ovarian Function Suppression
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
DrugBank: Plasma protein fraction (human) (DB13968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
Trial: NCT05501665
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given carboplatin
Trial: NCT05501665
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given nab-paclitaxel
Trial: NCT05501665
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given pemetrexed
Trial: NCT05188729
Drug: LTX-315 Part 1
RxNorm normalized name: Echinacea, aerial parts
DrugBank: LTX-315 (DB12748)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTX-315 once-daily dosing; starting total daily dose of 2 mg for the first subject. Ascending once-daily 1 mg dosing increments (eg, 2 mg on Day 1, 3 mg on Day 2). Subjects may be treated for a maximum of 2 weeks and a maximum total daily dose of 8 mg in Part 1. The starting dose will be escalated between subject cohorts in 1-mg increments after the previous cohort has completed Week 1 dosing (the DLT observation period).
Trial: NCT05188729
Drug: VP-315 Part 2
RxNorm normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VP-315 once-daily dosing; Part 2 will be initiated upon completion of Part 1 to determine the optimal dosing regimen of VP-315. There were no DLTs observed in Part 1 of the study and the maximum dose of 8 mg was achieved. Therefore, the dose to be evaluated in Part 2 will be a total daily dose of 8 mg in 4 Cohorts.
Trial: NCT05963386
Drug: 177Lu-DOTA-EB-FAPI radionuclide therapy
RxNorm normalized name: 177Lu-DOTA-octreotate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.3 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
Trial: NCT05287464
Drug: pembrolizumab plus axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: collect global experiences with the use of immuno-combinations in patients with metastatic RCC
Trial: NCT06798363
Drug: propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: different dose
Trial: NCT06469944
Drug: Levoleucovorin
RxNorm normalized name: Levoleucovorin
DrugBank: Levoleucovorin (DB11596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via IV infusion.
Trial: NCT06469944
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered via IV infusion
Trial: NCT05431777
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real world setting
Trial: NCT05387759
Drug: Aticaprant Supratherapeutic Dose
RxNorm normalized name: Aticaprant
DrugBank: Aticaprant (DB12341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aticaprant supratherapeutic dose capsule will be administered orally.
Trial: NCT05387759
Drug: Aticaprant Therapeutic Dose
RxNorm normalized name: Moisturel Therapeutic
DrugBank: Aticaprant (DB12341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aticaprant therapeutic dose capsule will be administered orally.
Trial: NCT05387759
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin capsule will be administered orally.
Trial: NCT04844424
Drug: Milvexian
RxNorm normalized name: Milvexian
DrugBank: Milvexian (DB16233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Trial: NCT05897385
Drug: Lignocaine
RxNorm normalized name: Lignocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
Trial: NCT05621759
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcineurin-inhibitor produced by Astellas.
Trial: NCT05621759
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective T cell co-stimulation modulator produced by Bristol-Myers Squibb.
Trial: NCT04847063
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 2, intraperitoneal (IP) Mitomycin C monotherapy: dosing divided into two 60-mL syringes, 30 mg per syringe. 30 mg will be given at time = 0, and the remaining 10 mg of the dose will be given at time = 60 minutes. Part of Arm 4: Mitomycin C co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
Trial: NCT04847063
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of Arms 3 and 4, intraperitoneal (IP)cisplatin co-therapy: 75 mg/m2 for 60 minutes, mixed in 1 L of 0.9% sodium chloride. For cisplatin-based HIPEC, intravenous sodium thiosulfate given as a loading dose of 7.5 g/m2 in 150 mL 0.9% sodium chloride at the time of introducing cisplatin into the perfusion circuit, followed by a 12-hour pump-based infusion of 25.56 g/m2 in 1 L 0.9% sodium chloride
Trial: NCT04847063
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm 1, intraperitoneal (IP) Oxaliplatin: 200 mg/m2 for 90 minutes, mixed in 250 mL of 5% dextrose solution. For oxaliplatin-based HIPEC, intravenous 5-fluorouracil given at a dose of 400 mg/m2 in 250 mL 0.9% sodium chloride over 10 minutes, co-administered with intravenous leucovorin at 20 mg/m2 in a separate bag of 250 mL 0.9% sodium chloride
Trial: NCT04847063
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of Arm 1, for oxaliplatin-based HIPEC: intravenous 5-fluorouracil given at a dose of 400 mg/m2 in 250 mL 0.9% sodium chloride over 10 minutes, co-administered with intravenous leucovorin at 20 mg/m2 in a separate bag of 250 mL 0.9% sodium chloride
Trial: NCT04847063
Drug: Sodium Thiosulfate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of Arms 3 and 4, for cisplatin-based HIPEC: intravenous sodium thiosulfate given as a loading dose of 7.5 g/m2 in 150 mL 0.9% sodium chloride at the time of introducing cisplatin into the perfusion circuit, followed by a 12-hour pump-based infusion of 25.56 g/m2 in 1 L 0.9% sodium chloride
Trial: NCT06510374
Drug: Nadofaragene Firadenovec
RxNorm normalized name: Nadofaragene firadenovec
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification.
Trial: NCT06412666
Drug: Aficamten
RxNorm normalized name: Aficamten
DrugBank: Aficamten (DB18490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT04419272
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg twice per day, at 8am and 12pm, for one week, then increased to 20mg twice daily, at 8am and 12pm, for the next 7 weeks during the double-blinded period.
Trial: NCT04419272
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the open-label extension phase, dosing will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 7 weeks.
Trial: NCT05537233
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
Trial: NCT04938765
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Effect of 40mg/kg Magnesium sulfate bolus dosed to ideal body weight on intraoperative neuromonitoring
Trial: NCT06384456
Drug: Topical TRanexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mL of 100mg/mL TXA will be administered into the surgical wound prior closure.
Trial: NCT05150652
Drug: Anastrozole 1mg
RxNorm normalized name: ANASTROZOLE 1MG TAB
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 1mg of anastrozole once daily, orally, for up to six cycles of 28 days.
Trial: NCT05150652
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 2.5mg of Letrozole once daily, orally, for up to six cycles of 28 days.
Trial: NCT05150652
Drug: Exemestane 25 mg
RxNorm normalized name: exemestane 25 MG
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 25mg of Exemestane once daily, orally, for up to six cycles of 28 days.
Trial: NCT05150652
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 20mg of Tamoxifen once daily, orally, for up to six cycles of 28 days.
Trial: NCT06255912
Drug: LTC004 + MIL-97+chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTC004 + MIL-97+chemotherapy
Trial: NCT05392530
Drug: Macitentan
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan film coated tablets will be administered orally as per assigned treatment sequence.
Trial: NCT06647069
Drug: DR-0201
RxNorm normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DR-0201 is a bispecific antibody
Trial: NCT04960124
Drug: JNJ-42847922
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.
Trial: NCT05705336
Drug: Tranexamic Acid Oral Product
RxNorm normalized name: tranexamic acid Oral Product
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision.
Trial: NCT05305924
Drug: Fulvestrant Run-In
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
Trial: NCT00002432
Drug: Foscarnet sodium
RxNorm normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00304668
Drug: dapivirine (TMC120) vaginal gel
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04105062
Drug: LS301
RxNorm normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine
Trial: NCT04985812
Drug: JNJ-67484703
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-67484703.
Trial: NCT04988256
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to cyclosporine will be treated as mentioned under Arm/Group Description
Trial: NCT04988256
Drug: Methylprednisolone and Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients randomized to steroids will initially be treated with IV methylprednisolone and eventually started on an oral prednisone taper.
Trial: NCT05362513
Drug: Ivermectin Tablets
RxNorm normalized name: Ivermectin Tablets
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group B received a single dose of oral ivermectin 200 mcg per kg
Trial: NCT05362513
Drug: Permethrin Cream
RxNorm normalized name: Permethrin Cream
DrugBank: Permethrin (DB04930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A received Permethrin 5% twice with a one-week interval.
Trial: NCT04705402
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol (Israeli Brand Name: Osmitrol) is in the osmotic diuretic pharmacologic categoryaccording to the American Hospital Formulary Service (AHFS) database. . During the procedure, volume of 2.8 cc / kg body weight of the solution bag (either mannitol or saline 0.9%) will be given. The bag itself will be covered so it cannot be identified which solution is in it and marked per patient.~Mannitol is injected by intravenous infusion using an I-vac pump and infused over 15 minutes.
Trial: NCT05554406
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC or IV
Trial: NCT05554406
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05554406
Drug: Daunorubicin Hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05554406
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
RxNorm normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05554406
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04634552
Drug: Talquetamab
RxNorm normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talquetamab will be administered SC until disease progression.
Trial: NCT05646381
Drug: Pelacarsen (TQJ230) 80mg
RxNorm normalized name: Pelacarsen
DrugBank: Pelacarsen (DB16284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelacarsen (TQJ230) 80mg
Trial: NCT04951609
Drug: Seltorexant
RxNorm normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of seltorexant.
Trial: NCT04619420
Drug: JNJ-63733657
RxNorm normalized name: Immunoglobulin G1, anti-(human phosphorylated tau protein) (human-Mus musculus monoclonal JNJ-63733657 γ1-chain), disulfide with human-Mus musculus monoclonal JNJ-63733657 κ-chain, dimer
DrugBank: Posdinemab (DB18941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-63733657 low or high dose will be administered by IV infusion.
Trial: NCT04705402
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
Trial: NCT04872634
Drug: GC
RxNorm normalized name: EGC
DrugBank: Epigallocatechin (DB03823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine; 1000mg/m2, Day 1, Day 8, 4-cycle administration, Mixed with normal saline 50ml and administered into a vein for 30 min.~Carboplatin; AUC 5, Day 1, 4-cycle administration, Mixed with 5% Dextrose 200ml and administered into a vein for 1 hour.
Trial: NCT05739981
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2 IV
Trial: NCT05739981
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 5-6 IV
Trial: NCT05739981
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
Trial: NCT04214249
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given via continuous IV infusion
Trial: NCT04214249
Drug: Daunorubicin Hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04214249
Drug: Idarubicin Hydrochloride
RxNorm normalized name: Idarubicin Hydrochloride
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05640271
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 80 mg IV dose (one time per patient)
Trial: NCT05483400
Drug: Tiragolumab and atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.
Trial: NCT04978012
Drug: Fluzoparib and Camrelizumab
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.
Trial: NCT04550104
Drug: Olaparib Oral Tablet [Lynparza]
RxNorm normalized name: olaparib Oral Tablet [Lynparza]
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablet
Trial: NCT04550104
Drug: Ceralasertib
RxNorm normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT04550104
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500mg iv infusion
Trial: NCT04232800
Drug: Riboflavin
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
Trial: NCT00249119
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no